- Home
- ELP vs IONS Comparison
ELP vs IONS Comparison
Compare ELP & IONS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ELP
- IONS
- Stock Information
- Founded
- ELP 1954
- IONS 1989
- Country
- ELP Brazil
- IONS United States
- Employees
- ELP N/A
- IONS N/A
- Industry
- ELP Electric Utilities: Central
- IONS Biotechnology: Pharmaceutical Preparations
- Sector
- ELP Utilities
- IONS Health Care
- Exchange
- ELP Nasdaq
- IONS Nasdaq
- Market Cap
- ELP 6.9B
- IONS 6.8B
- IPO Year
- ELP 1997
- IONS 1991
- Fundamental
- Price
- ELP $9.54
- IONS $61.10
- Analyst Decision
- ELP
- IONS Buy
- Analyst Count
- ELP 0
- IONS 17
- Target Price
- ELP N/A
- IONS $67.88
- AVG Volume (30 Days)
- ELP 180.7K
- IONS 3.3M
- Earning Date
- ELP 11-05-2025
- IONS 11-05-2025
- Dividend Yield
- ELP 4.62%
- IONS N/A
- EPS Growth
- ELP 30.24
- IONS N/A
- EPS
- ELP 0.19
- IONS N/A
- Revenue
- ELP $4,381,150,343.00
- IONS $944,050,000.00
- Revenue This Year
- ELP N/A
- IONS $24.30
- Revenue Next Year
- ELP $6.59
- IONS $7.39
- P/E Ratio
- ELP $11.94
- IONS N/A
- Revenue Growth
- ELP 8.47
- IONS 16.05
- 52 Week Low
- ELP $5.72
- IONS $23.95
- 52 Week High
- ELP $9.56
- IONS $64.72
- Technical
- Relative Strength Index (RSI)
- ELP 66.28
- IONS 72.08
- Support Level
- ELP $8.90
- IONS $62.79
- Resistance Level
- ELP $9.39
- IONS $64.61
- Average True Range (ATR)
- ELP 0.16
- IONS 2.40
- MACD
- ELP 0.04
- IONS 1.04
- Stochastic Oscillator
- ELP 98.01
- IONS 84.27
About ELP Companhia Paranaense de Energia (COPEL)
Cia Paranaense De Energia Copel is engaged in the areas of generation, transmission, commercialization and distribution of energy. It operates a comprehensive and effective electrical system with its own generating plants, transmission lines, substations, electrical lines and grids of the distribution system. The company's reportable segments include Power generation and transmission, Power distribution, GAS, Power sale, Services, and Holding. The majority of its revenue is generated from the Power generation and transmission segment under which it produces electricity from hydraulic, wind, and thermal projects and provides services of transmission and transformation of electric power and other related services.
About IONS Ionis Pharmaceuticals Inc.
Ionis Pharmaceuticals is the leading developer of antisense technology to discover and develop novel drugs. Its broad clinical and preclinical pipeline targets a wide variety of diseases, with an emphasis on cardiovascular, metabolic, neurological, and rare diseases. Ionis and Biogen brought Spinraza to market in 2016 as a treatment for spinal muscular atrophy, and Biogen launched ALS drug Qalsody in 2023. Ionis brought two additional drugs to market via its cardiovascular-focused subsidiary Akcea, including ATTR amyloidosis drug Tegsedi (2018) and cardiology drug Waylivra (Europe, 2019). Ionis and AstraZeneca launched polyneuropathy drug Wainua in 2024. Ionis received FDA approval in 2024 for Tryngolza for a rare high-triglyceride syndrome, marking its first independent launch.